Apixaban
Portal Vein Thrombosis
Asian Institute Of Medical SciencesSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
12 Active assets in the Portal Vein Thrombosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
Lenvatinib First Hospital of China Medical University | Phase 4 | BBB |
Warfarin Kafrelsheikh University | Phase 4 | BB |
Nadroparin Shanghai Zhongshan Hospital | Phase 4 | BB |
Enoxaparin Institute of Liver and Biliary Sciences, India | Phase 4 | BB |
View all 26 →
Same molecule, other indications
Apixaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →